Clearance of pediatric actinic prurigo with dupilumab

Eickstaedt, Joshua; Starke, Samuel J.; Krakora, Dan; Hinshaw, Molly; Arkin, Lisa M.

doi:10.1111/pde.14311

Cited by 15 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic photodermatoses including chronic actinic dermatosis (CAD) and actinic prurigo are induced by exposure to UV-radiation and can resemble photosensitive AD. Reports showed efficacy of dupilumab in 16 cases of CAD ( Table 8 ) [ 252 , 253 , 254 , 255 , 256 , 257 , 258 ] as well as in a pediatric patient with actinic prurigo [ 259 ], leading to higher minimal erythema doses in repeated UV-phototesting in some cases.…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For severe AP, thalidomide and cyclosporine are classically used treatments, but patients frequently flare upon withdrawal thus making chronic use necessary. 1 AP patients usually require chronic therapy, and the potentially severe side effects particularly with chronic use of thalidomide and cyclosporine limit their utility, especially in the pediatric population. 1 , 3 Antimalarials and phototherapy with narrowband UV-B or psoralen plus UV-A have also been used to desensitize patients to UV activity.…”

Section: Discussionmentioning

confidence: 99%

“…Actinic prurigo (AP) is a rare chronic photodermatosis typically seen in indigenous populations of North, Central, and South America. 1 Approximately 93% of Latin American patients with AP are found to be positive for HLA-DR4, of which 80% have the DRB1∗0407 allele. 2 These individuals are predisposed to type IV hypersensitivity reactions to UV radiation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dupilumab as treatment of actinic prurigo suggests pathophysiologic mechanism of disease: A case series

Barker,

Sattele,

Strat

et al. 2024

JAAD Case Reports

View full text Add to dashboard Cite

“…Clinical remission and improved quality of life were observed following three courses of 300 mg monthly for 6 months and a fourth year-long course. Clearance of pediatric actinic prurigo and adult actinic dermatosis has also been reported with dupilumab, an interleukin-4 receptor antagonist that disrupts the Th2 immunologic pathway [10,11]. Adult patients with resistant chronic actinic dermatitis have also responded to tofacitinib therapy, an oral Janus kinase inhibitor [12].…”

Section: Idiopathic Photodermatosesmentioning

confidence: 98%

Photodermatoses: what's new

Scollan

Lauren

2022

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of reviewThe purpose of this review is to summarize and highlight the recent literature in photodermatoses. In the past year, there have been many developments in this heterogeneous group of conditions. Recent findingsThis review is divided by photodermatoses type, which include idiopathic photodermatoses, photodermatoses secondary to exogenous agents, photodermatoses secondary to endogenous agents (the porphyrias), and genodermatoses. The idiopathic photodermatoses section focuses on case series and reports highlighting new disease presentations or further disease characterization and new treatment strategies for these disorders. The second section discusses a unique case and has a brief update on photoallergens. Clinical, diagnostic, and treatment updates for porphyrias are discussed in Section 3. For genodermatoses, we discuss complications and neoplastic risk of xeroderma pigmentosum and a few highlights from other rare disorders. Finally, we conclude with a brief overview of photoprotection updates, from assessing sun-damaged skin to the most effective photoprotective agents.

show abstract

Clearance of pediatric actinic prurigo with dupilumab

Cited by 15 publications

References 5 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab as treatment of actinic prurigo suggests pathophysiologic mechanism of disease: A case series

Photodermatoses: what's new

Contact Info

Product

Resources

About